The currently used tumor-node metastasis (TNM) staging method is generally not applicable to patients with unresectable esophageal carcinomas. There is a need for both an efficient, easy-to-perform clinical classification and for identification of pretherapeutic prognostic factors that would be useful for oncologists, one of which is tumor volume. Methods: Records of 148 patients, admitted to hospital during the period January 1993 to December 2001, were evaluated retrospectively. Median age was 65.7 years (range, 35.5-85.5 years). Most patients had SCC (84.5%). Using the computed tomography (CT) scan classification, tumors were recorded as follows: 1 T1, 42 T2, 93 T3, 6 T4, 2 Nx, 72 N0, 74 N1. Tumor volume from the CT scans was determined as the sum of 2 opposed truncated cones. Median tumor volume was 57.5 cm 3 (range, 0.6 -288 cm 3 ). Results: Median follow-up was 15.1 month (range, 0.3-82.8 months). Survival rates at 1, 2, and 3 years were 42.5%, 21.6%, and 8%, respectively. Prognostic factors identified by univariate analysis were: dysphagia grade Ն2, other histology than squamous cell, tumor location below the carina, age Ͻ65 years and tumor volume Ն100 cm 3 . Prognostic factors identified with multivariate analysis were: dysphagia grade Ն2 (P ϭ 0.013), weight loss Ն10% (P ϭ 0.047), tumor location below the carina (P ϭ 0.002), and tumor volume Ն100 cm 3 (P ϭ 0.041). Conclusions: For patients that the TNM staging system is not applicable, tumor volume is a new powerful determinant of survival. Further clinical trials need to be carried out to validate this prospectively.
Objective:
The currently used tumor-node metastasis (TNM) staging method is generally not applicable to patients with unresectable esophageal carcinomas. There is a need for both an efficient, easy-to-perform clinical classification and for identification of pretherapeutic prognostic factors that would be useful for oncologists, one of which is tumor volume. Methods: Records of 148 patients, admitted to hospital during the period January 1993 to December 2001, were evaluated retrospectively. Median age was 65.7 years (range, 35.5-85.5 years). Most patients had SCC (84.5%). Using the computed tomography (CT) scan classification, tumors were recorded as follows: 1 T1, 42 T2, 93 T3, 6 T4, 2 Nx, 72 N0, 74 N1. Tumor volume from the CT scans was determined as the sum of 2 opposed truncated cones. Median tumor volume was 57.5 cm 3 (range, 0.6 -288 cm 3 ). Results: Median follow-up was 15.1 month (range, 0.3-82.8 months). Survival rates at 1, 2, and 3 years were 42.5%, 21.6%, and 8%, respectively. Prognostic factors identified by univariate analysis were: dysphagia grade Ն2, other histology than squamous cell, tumor location below the carina, age Ͻ65 years and tumor volume Ն100 cm 3 . Prognostic factors identified with multivariate analysis were: dysphagia grade Ն2 (P ϭ 0.013), weight loss Ն10% (P ϭ 0.047), tumor location below the carina (P ϭ 0.002), and tumor volume Ն100 cm 3 (P ϭ 0.041). Conclusions: For patients that the TNM staging system is not applicable, tumor volume is a new powerful determinant of survival. Further clinical trials need to be carried out to validate this prospectively. E sophageal cancer (EC) is a highly aggressive disease with poor prognosis. Data from the Eurocare III study indicates a 5-year relative survival rate of about 10% for all patients, for the period 1990 through 1994. 1 The squamous cell type still predominates but the incidence of adenocarcinomas is rapidly increasing. [2] [3] [4] Surgery is recommended for the 10% to 20% of operable patients at the early disease stage. 5 About 60% of the patients have a locoregional disease extension that precludes any surgical intervention and/or they are unfit for surgery for medical reasons. In this case, the standard treatment is exclusive chemoradiation (ECRT) based on the results of the Radiation Therapy Oncology Group (RTOG) trial 85-01. 6 Assessment of the extent of the disease is important to determine the tumor-node stage and to plan optimal management. In 1987 the TN staging system for EC was revised; only pathologic stages were included, and since that time, International Union against Cancer (UICC) classifications have strictly adhered to this concept. 7 The current UICC staging system is thus not applicable to inoperable patients. Endoscopic ultrasonography (EUS), which is the best procedure for determining the locoregional extension of early disease, may not be applicable in about 30% of the patients because of unpassed stenosis. 8 Although miniprobes are able to pass beyond tumor stenosis and they provide more accurate T staging, they are unable to fully image large tumors and are not satisfactory for evaluating regional lymph nodes. 9 In a randomized phase III study conducted by the Foundation Francaise de Cancerologie Digestive (FFCD) and the European Organization for Research and Treatment of Cancer (EORTC), which tested preoperative chemoradiation versus surgery alone, a staging system based on the results of thoracic computed tomography (CT) scans was used. A positive predictive value of 84% for T3 and 75% for N1 10 was found. The aim of the present study was to identify the variables that determine the outcome of patients treated with chemoradiation with a special focus on the TN stage as determined by chest CT scan and the tumor volume (TV).
PATIENTS AND METHODS
All patients in the radiation departments of Besançon and Dijon (both in France) were treated with chemoradiation and reviewed. Patient files for 387 patients with EC, treated from January 1, 1993 to December 12, 2001 were retrospectively analyzed. Patients who were treated with ECRT with a curative intent were selected. Two hundred and thirty-nine patients were excluded for the following reasons: synchronous metastases, 61 patients; preoperative chemoradiation, 49 patients; postoperative chemoradiation, 17 patients; palliative radiotherapy, 19 patients; second primary, 79 patients; brachytherapy boost, 8 patients; synchronous esophageal second cancer, 2 patients; severe cirrhosis, 1 patient; missing data, 3 patients. A total of 148 patients were included in the analysis. The following data were recorded for each patient: age, sex, World Health Organization (WHO) performance status, weight loss from baseline, dysphagia grade, serum proteinemia, creatinine and hemoglobin levels, tumor type (squamous cell versus adenocarcinoma), tumor differentiation, and tumor location with regard to the carina. The scale used for the assessment of dysphagia is shown in Table 1 . The TNM staging was assessed using 2 scoring systems. 9, 10 The 1978 UICC classification was based on data from endoscopy, barium esophagogram, or both. In this classification, T1 is defined as a tumor measuring 5 cm or less and not circumferential; T2 as a tumor measuring more than 5 cm or circumferential and T3 as a tumor with an extraesophageal invasion. Nodes were classified as N1 if diagnosed on a chest x-ray for a thoracic tumor or if palpable and movable in the unilateral supraclavicular fossa, for a cervical tumor. Cervical tumors with regional, nonpalpable nodes, diagnosed on a chest x-ray, were classified as N2. The CT scan-based T and N stages and TV were retrospectively assessed using the pretherapeutic CT scan from each patient. Up to 1999, CT scans were routinely performed using joined slice thickness of 10 mm at the beginning of the study where multislice CT scans have been used since then with joined slice thickness of 5 mm. The T stage, using a validated radiologic classification, was defined by the maximal transverse diameter of the esophageal tumor: less than 1 cm was defined as T 1 ; between 1 and 3 cm as T 2 and larger than 3 cm as T 3 . 10 Tumors that had invaded any neighboring structures were classified as T 4 . Lymph nodes were classified as N 1 (invaded) if the maximal transverse diameter was longer than 1 cm; otherwise they were classified as N 0 . For the calculation of the tumor volume, the tumor was assimilated and represented as 2 opposing truncated cones (Fig. 1) . The following formula was applied TV ϭ ͓( ⅐ H)/16͔ ϫ (M1 2 ϩ 2.M2 2 ϩ M3 2 ). M1 and M3 were the transverse diameters of the tumor at its cranial and caudal extremities, respectively. M 2 was the maximal transverse diameter and H the tumor height. All measurements were expressed in millimeters. The TN staging and tumor measurements were performed independently by 2 radiation oncologists. A third reviewer was consulted when there was a 10% volume variation. Two ECRT schemes were used during the period. One was the RTOG 85.01 scheme, which delivered 50 Gy over 5 weeks with a field reduction after 30 Gy. Four courses of chemotherapy were delivered at weeks 1, 5, 8, and 11. The schedule for each course was: cisplatin 75 mg/m 2 at day 1; 5-FU 1000 mg/m 2 /d1-d4. 6 The other was the Foundation Française de Cancerologie Digestive (FFCD) 91.02 scheme, which delivered ECRT in 4 1-week sequences with a 2-week gap between each sequence. The schedule for each sequence was: 15 Gy dose radiation in 5 daily fractions; Cisplatin 15 mg/m 2 d1-d5 and 5-FU 800 mg/m 2 continuous infusion d1-d5.
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Statistical Analysis
Survival was calculated from the first day of treatment to the most recent follow-up contact or to the date of death and was estimated as a fraction of time by the Kaplan-Meier method. 12 The prognostic value of each variable for overall survival was assessed by univariate analysis using a log-rank test; multivariate analysis was assessed using the step-wise Cox proportional hazards regression model. 13 Fisher exact 
RESULTS
Patients, tumors, and treatment characteristics are shown in Tables 2 and 3 , respectively. A 10% weight loss from baseline was observed in 48 patients (33%) and 37 patients (25%) had a World Health Organization (WHO) performance status Ն2. There were 125 patients (84.5%) who had a squamous cell type tumor. A T 3 -T 4 tumor stage was observed in 99 patients (66.9%) and 74 patients (50%) were classified as N1. The mean TV was 57.5 cm 3 (range, 0.6 -288). The 85.01 RTOG treatment was delivered to 117 patients (79%). Planned treatment was discontinued in 10 patients (6.8%). The mean proteinemia level was 68.6 g/l (range, 37-86). The mean serum creatinine level was 74.8 mol/l (range, 66 -131). The mean hemoglobin level was 13.4 g/dl (range, 9 -18.6).
Survival
When the analysis was performed, 90 patients (61%) had died. The median follow-up for living patients was 15.1 month (range, 0.3-82.8 months). The rates of locoregional failure, distant failure, or both, were 44%, 3%, and 5%, respectively. A second primary was diagnosed in 2 patients. The median survival was 7 months (confidence interval 95%: 6 -8.2). The 1-and 3-year survival rates were 42.5% and 8%, respectively.
Prognostic Factors
The results of the univariate analysis of patient, tumor and treatment-related factors with respect to overall survival are shown in Table 4 . Several cut-off points for TV were analyzed. P-values for T status using the UICC 78 classification or CT-scan classification were 0.18 and 0.84, respectively. P value for N status using the CT-scan classification was 0.58. No statistical difference was observed between the 2 regimen of ECRT: conventional versus split course (P ϭ 0.7). Because of both the progresses in CT-scan image acquisition and the increased conformal radiation delivery that occurred during the 9-year range of the study, a separate evaluation of the 1993 through 1998 period versus the 1999 through 2001 period was performed. Survival rates were (Table 5) . Fisher exact test found that tumor location and TV were correlated: larger tumors were more frequently located below the carina and smaller tumors above (P Ͻ 0.0001).
DISCUSSION
Chemoradiation is the standard treatment of patients with locally advanced and inoperable EC. 6 With a 50-Gy radiation dose and chemotherapy combining 5-FU-cisplatin, 2 randomized RTOG trials have shown reproducible results with median, and 3-and 5-year survivals of 14.1 month, 30% and 24%, respectively. 6, 15 We observed poorer results: only 8% of patients survived 3 years after treatment. Patients in our study had more advanced stages with 50% of patients at the N1 stage, compared with about 15% in the RTOG trials. Because surgery is still considered the standard approach for operable patients with stage III esophageal cancer in France, patients referred for ECRT have poor profile characteristics with high comorbidity.
In a randomized trial that compared preoperative chemoradiation to surgery alone in squamous cell tumors, we found dysphagia grade 2 and over were associated with a significant decrease in survival; 10 we observed the same results in the present study. Weight loss has been recognized as a significant negative prognostic factor in patients treated with surgery 16 or with chemoradiation alone. 17 A Recursive Partitioning Analysis of pretreatment patient-related and tumor-related variables of 416 patients treated with ECRT in 3 RTOG trials showed that weight loss of Ͻ10% versus Ն10% in the 6 months before treatment was the only variable that significantly influenced the overall survival. 18 Results from our study are in agreement, confirming that a Ն10% weight loss before ECRT is associated with decreased survival. The survival rate was also worse for patients with tumor locations below the carina. In the randomized study we performed in operable patients, we observed that a tumor located above the carina was the only significant prognostic factor for survival in the multivariate analysis. 10 We have 3 explanations for this. First, in surgical series, tumors located below the carina are adenocarcinomas in 80% of patients. Distant failures are significantly higher in this population, giving them a worse prognosis. 19 Second, we suggest that tumors located below the carina spread unnoticed before the appearance of the first symptom. This is probably because of the larger anatomic space because of more distant boundaries. Third, the FFCD-EORTC study included patients with squamous cell cancers located in the upper and middle esophagus and with a lower disease stage based on the CT-scan staging system.
In the present study, we found that TV had a significant impact on survival. Tumor volume has already been studied in cervical and head and neck cancers. 20 -22 A recent study for laryngeal carcinomas has shown that local control is significantly correlated with TV. 20 In nasopharyngeal cancers, similar results were obtained with a significant decrease in disease-specific survival in patients with large primary TV, whereas T stage had no prognostic significance. 21 A study based on data from magnetic resonance imaging in cervical cancers has also demonstrated that, for patients with bulky diseases, TV provides more relevant prognostic value and practicable information than International Federation of Gynecology and Obstetrics (FIGO) classification. 22 Several reports have revealed that the TV is also a useful prognostic factor in radiation therapy for various stages of nonsmall-cell lung cancer. [23] [24] [25] For resectable EC, only N status defined by CT scan appeared to have an impact on survival, whereas T status defined with a CT scan does not appear to have any impact. 10 Nevertheless, the positive predictive values of the disease stage classification based on the CT scan for T3 tumors, N0 and N1 were 84%, 49%, and 75%, respectively. These results indicate the need for a more accurate method for the staging of EC. Recently, a Recursive Partitioning Analysis of T, N, and M status in EC has shown that the American Joint Committee on Cancer (AJCC) staging system, which is similar to the UICC, is inappropriate for T status. 26 Therefore, the current TNM staging system is not only inapplicable to routine practice for inoperable patients, but is also recognized as having no prognostic value. The 1983 AJCC system and the 1978 UICC classification used information from endoscopy and barium esophagram 27, 28 and were more predictive of the outcome in patients not treated with surgery. 29 EUS was accurate in assessing the depth of tumor infiltration (overall accuracy was 89%), but its routine is impeded for 2 reasons: unpassed stenosis occurred in 25% of the patients, and its ability to detect metastatic lymph nodes was not good (specificity 50%). 8, 9 Although nonoptical wire-guided EUS probes and EUS-guided fine-needle aspiration are more accurate, they are not used in a routine examination. It appears that TV could be a relevant prognostic factor. Moreover, this new prognostic factor is correlated with tumor location, thus also suggesting that tumors below the carina have a worse prognosis. There are, however, still some imperfections in the method used to determine the tumor because of the retrospective analysis and the possible variations in quality of the CT thoracic scan. Today, as part of their standard procedure, radiation oncologists delineate the tumor on each of the slices using a CT-based simulation procedure. Gross tumor volume (GTV) 30 on joined slices may be easily calculated using computers and the software associated with the treatment planning system. The length, determined by a PET-CT correlated better with endoscopy than with CT scan. 31 Fused PET-CT imaging and modern tools should be able to specify the boundaries of the tumor that may be unclear and incomplete on the CT scan, especially in the cranio-caudal axis. Therefore, we suggest that further clinical trials be carried out which identify and stratify TV in the tumor characteristics for all patients with inoperable EC. Tumor volume should be used in prospective clinical trials to definitively validate this simple tumor characteristic as a useful prognostic factor.
